OncoSec Medical Inc (ONCSQ)

[hschlauch]

(WO2016154473) METHOD FOR THE TREATMENT OF MALIGNANCIES

Pub. No.: WO/2016/154473 International Application No.: PCT/US2016/024079
Publication Date: 29.09.2016 International Filing Date: 24.03.2016

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016154473&recNum=4&maxRec=13&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28oncosec%29&tab=PCT+Biblio

Accordingly, what is needed in the art is a combination therapy of intratumoral immunostimulatory cytokine therapy and a checkpoint inhibitor, co-delivered encoded on a plasmid and delivered via electroporation to the tumor;

In another embodiment, the checkpoint inhibitor(s) is encoded on the plasmid encoding the immunostimulatory cytokine and delivered to the cancerous tumor by electroporation therapy. The checkpoint inhibitor is an antagonist of at least one checkpoint target of Table 1 .

...

In Table 1 they include the following checkpoint targets:

CTLA-4, PD-1, PD-L1, LAG-3, TIM3, KIR, BTLA, A2aR, HVEM

Yes, they are indeed encoding checkpoint inhibitors on plasmids!

And then you have the relationship with researchers at Ku Leuven, working on DNA encoded monoclonal antibodies.